Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism

Samantha J. Podurgiel, Tiahna Spencer, Rotem Kovner, Younis Baqi, Christa E. Müller, Merce Correa, John D. Salamone

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tremulous jaw movements (TJMs) have become a commonly used rat model of Parkinsonian tremor. TJMs can be induced by a number of neurochemical conditions that parallel those seen in human Parkinsonism, including DA depletion, DA antagonism, and cholinomimetic administration, and can be reduced by various antiparkinsonian agents. TJMs typically occur in bursts with the peak frequency in the range of 3-7.5 Hz, which is similar to the Parkinsonian tremor frequency range. While the vast majority of this work has been done using rats, current efforts have focused on extending the TJM model to mice. The aim of the present studies was to establish a mouse model of Parkinsonian resting tremor using the anticholinesterase galantamine, and to investigate the effects of adenosine A2A antagonism on galantamine-induced TJMs. Galantamine significantly induced TJMs in a dose-dependent manner (0.5, 1.0, 1.5, 2.0, 2.5 mg/kg IP). The TJMs tended to occur in bursts in the 3-7.5 Hz frequency range, with a peak frequency of approximately 6 Hz. Systemic administration of the adenosine A2A antagonist MSX-3 (2.5, 5.0, 10.0 mg/kg) significantly attenuated galantamine-induced TJMs. Co-administration of MSX-3 also altered the local frequency of galantamine-induced TJMs, decreasing the peak frequency from approximately 6 Hz to 5 Hz, though the vast majority of TJMs remained in the frequency range characteristic of Parkinsonian resting tremor. These results indicate that adenosine A2A antagonism is capable of reducing anticholinesterase-induced TJMs in mice. Extending the TJM model to mice gives researchers an additional avenue for investigating drug-induced Parkinsonism and tremorogenesis, and could be a useful addition to the study of motor abnormalities observed in mouse genetic models of Parkinsonism.

Original languageEnglish
Pages (from-to)62-67
Number of pages6
JournalPharmacology Biochemistry and Behavior
Volume140
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Galantamine
Cholinesterase Inhibitors
Tremor
Jaw
Adenosine
Rats
Parkinsonian Disorders
Antiparkinson Agents
Cholinergic Agents
Pharmaceutical Preparations
Genetic Models

Keywords

  • Acetylcholine
  • Basal ganglia
  • Parkinson's disease
  • Parkinsonism
  • Striatum
  • Tremulous jaw movements

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine : Reversal with adenosine A2A antagonism. / Podurgiel, Samantha J.; Spencer, Tiahna; Kovner, Rotem; Baqi, Younis; Müller, Christa E.; Correa, Merce; Salamone, John D.

In: Pharmacology Biochemistry and Behavior, Vol. 140, 01.01.2016, p. 62-67.

Research output: Contribution to journalArticle

Podurgiel, Samantha J. ; Spencer, Tiahna ; Kovner, Rotem ; Baqi, Younis ; Müller, Christa E. ; Correa, Merce ; Salamone, John D. / Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine : Reversal with adenosine A2A antagonism. In: Pharmacology Biochemistry and Behavior. 2016 ; Vol. 140. pp. 62-67.
@article{7173992f95054580b078361e6d81090c,
title = "Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism",
abstract = "Tremulous jaw movements (TJMs) have become a commonly used rat model of Parkinsonian tremor. TJMs can be induced by a number of neurochemical conditions that parallel those seen in human Parkinsonism, including DA depletion, DA antagonism, and cholinomimetic administration, and can be reduced by various antiparkinsonian agents. TJMs typically occur in bursts with the peak frequency in the range of 3-7.5 Hz, which is similar to the Parkinsonian tremor frequency range. While the vast majority of this work has been done using rats, current efforts have focused on extending the TJM model to mice. The aim of the present studies was to establish a mouse model of Parkinsonian resting tremor using the anticholinesterase galantamine, and to investigate the effects of adenosine A2A antagonism on galantamine-induced TJMs. Galantamine significantly induced TJMs in a dose-dependent manner (0.5, 1.0, 1.5, 2.0, 2.5 mg/kg IP). The TJMs tended to occur in bursts in the 3-7.5 Hz frequency range, with a peak frequency of approximately 6 Hz. Systemic administration of the adenosine A2A antagonist MSX-3 (2.5, 5.0, 10.0 mg/kg) significantly attenuated galantamine-induced TJMs. Co-administration of MSX-3 also altered the local frequency of galantamine-induced TJMs, decreasing the peak frequency from approximately 6 Hz to 5 Hz, though the vast majority of TJMs remained in the frequency range characteristic of Parkinsonian resting tremor. These results indicate that adenosine A2A antagonism is capable of reducing anticholinesterase-induced TJMs in mice. Extending the TJM model to mice gives researchers an additional avenue for investigating drug-induced Parkinsonism and tremorogenesis, and could be a useful addition to the study of motor abnormalities observed in mouse genetic models of Parkinsonism.",
keywords = "Acetylcholine, Basal ganglia, Parkinson's disease, Parkinsonism, Striatum, Tremulous jaw movements",
author = "Podurgiel, {Samantha J.} and Tiahna Spencer and Rotem Kovner and Younis Baqi and M{\"u}ller, {Christa E.} and Merce Correa and Salamone, {John D.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.pbb.2015.10.008",
language = "English",
volume = "140",
pages = "62--67",
journal = "Pharmacology, Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine

T2 - Reversal with adenosine A2A antagonism

AU - Podurgiel, Samantha J.

AU - Spencer, Tiahna

AU - Kovner, Rotem

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Correa, Merce

AU - Salamone, John D.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Tremulous jaw movements (TJMs) have become a commonly used rat model of Parkinsonian tremor. TJMs can be induced by a number of neurochemical conditions that parallel those seen in human Parkinsonism, including DA depletion, DA antagonism, and cholinomimetic administration, and can be reduced by various antiparkinsonian agents. TJMs typically occur in bursts with the peak frequency in the range of 3-7.5 Hz, which is similar to the Parkinsonian tremor frequency range. While the vast majority of this work has been done using rats, current efforts have focused on extending the TJM model to mice. The aim of the present studies was to establish a mouse model of Parkinsonian resting tremor using the anticholinesterase galantamine, and to investigate the effects of adenosine A2A antagonism on galantamine-induced TJMs. Galantamine significantly induced TJMs in a dose-dependent manner (0.5, 1.0, 1.5, 2.0, 2.5 mg/kg IP). The TJMs tended to occur in bursts in the 3-7.5 Hz frequency range, with a peak frequency of approximately 6 Hz. Systemic administration of the adenosine A2A antagonist MSX-3 (2.5, 5.0, 10.0 mg/kg) significantly attenuated galantamine-induced TJMs. Co-administration of MSX-3 also altered the local frequency of galantamine-induced TJMs, decreasing the peak frequency from approximately 6 Hz to 5 Hz, though the vast majority of TJMs remained in the frequency range characteristic of Parkinsonian resting tremor. These results indicate that adenosine A2A antagonism is capable of reducing anticholinesterase-induced TJMs in mice. Extending the TJM model to mice gives researchers an additional avenue for investigating drug-induced Parkinsonism and tremorogenesis, and could be a useful addition to the study of motor abnormalities observed in mouse genetic models of Parkinsonism.

AB - Tremulous jaw movements (TJMs) have become a commonly used rat model of Parkinsonian tremor. TJMs can be induced by a number of neurochemical conditions that parallel those seen in human Parkinsonism, including DA depletion, DA antagonism, and cholinomimetic administration, and can be reduced by various antiparkinsonian agents. TJMs typically occur in bursts with the peak frequency in the range of 3-7.5 Hz, which is similar to the Parkinsonian tremor frequency range. While the vast majority of this work has been done using rats, current efforts have focused on extending the TJM model to mice. The aim of the present studies was to establish a mouse model of Parkinsonian resting tremor using the anticholinesterase galantamine, and to investigate the effects of adenosine A2A antagonism on galantamine-induced TJMs. Galantamine significantly induced TJMs in a dose-dependent manner (0.5, 1.0, 1.5, 2.0, 2.5 mg/kg IP). The TJMs tended to occur in bursts in the 3-7.5 Hz frequency range, with a peak frequency of approximately 6 Hz. Systemic administration of the adenosine A2A antagonist MSX-3 (2.5, 5.0, 10.0 mg/kg) significantly attenuated galantamine-induced TJMs. Co-administration of MSX-3 also altered the local frequency of galantamine-induced TJMs, decreasing the peak frequency from approximately 6 Hz to 5 Hz, though the vast majority of TJMs remained in the frequency range characteristic of Parkinsonian resting tremor. These results indicate that adenosine A2A antagonism is capable of reducing anticholinesterase-induced TJMs in mice. Extending the TJM model to mice gives researchers an additional avenue for investigating drug-induced Parkinsonism and tremorogenesis, and could be a useful addition to the study of motor abnormalities observed in mouse genetic models of Parkinsonism.

KW - Acetylcholine

KW - Basal ganglia

KW - Parkinson's disease

KW - Parkinsonism

KW - Striatum

KW - Tremulous jaw movements

UR - http://www.scopus.com/inward/record.url?scp=84947998810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947998810&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2015.10.008

DO - 10.1016/j.pbb.2015.10.008

M3 - Article

C2 - 26459156

AN - SCOPUS:84947998810

VL - 140

SP - 62

EP - 67

JO - Pharmacology, Biochemistry and Behavior

JF - Pharmacology, Biochemistry and Behavior

SN - 0091-3057

ER -